[AGIO] Agios Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 43.15 Change: 1.78 (4.3%)
Ext. hours: Change: 0 (0%)

chart AGIO

Refresh chart

Strongest Trends Summary For AGIO

AGIO is in the long-term down -56% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-6 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 306.63% Sales Growth - Q/Q133.68% P/E-8.63
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-9.74% ROE-10.83% ROI
Current Ratio10.01 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin-51.61% Net Profit Margin-50.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.82 M Cash From Investing Activities44.99 M Cash From Operating Activities-25.59 M Gross Profit
Net Profit-4.96 M Operating Profit-5.2 M Total Assets474.34 M Total Current Assets364.14 M
Total Current Liabilities36.38 M Total Debt Total Liabilities47.52 M Total Revenue34.2 M
Technical Data
High 52 week75.11 Low 52 week42.73 Last close62.35 Last change5.93%
RSI68.62 Average true range2.74 Beta1.94 Volume828.59 K
Simple moving average 20 days13.04% Simple moving average 50 days18.89% Simple moving average 200 days3.15%
Performance Data
Performance Week5.16% Performance Month20.07% Performance Quart-5.23% Performance Half4.56%
Performance Year26.83% Performance Year-to-date35.22% Volatility daily2.87% Volatility weekly6.41%
Volatility monthly13.13% Volatility yearly45.49% Relative Volume130.51% Average Volume563.62 K
New High New Low

News

2019-06-18 08:40:12 | Agios AGIO Catches Eye: Stock Jumps 5.4%

2019-06-18 08:06:00 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-06-17 09:59:49 | Volatility 101: Should Agios Pharmaceuticals NASDAQ:AGIO Shares Have Dropped 50%?

2019-06-14 18:28:21 | Is Agios Pharmaceuticals Inc AGIO Going to Burn These Hedge Funds?

2019-06-13 08:02:28 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-06-11 08:03:03 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-06-10 13:12:44 | Agios to Present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019

2019-06-06 09:17:39 | Life sciences VC firm Third Rock raises $770M in its largest round ever

2019-06-05 16:00:00 | Agios Announces the Planned Retirement of Chief Scientific Officer, Scott Biller, Ph.D., Effective December 31, 2019

2019-06-04 08:04:31 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-06-03 08:00:00 | Agios Presents Updated Data from Phase 1 Studies of TIBSOVO® ivosidenib in Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia AML Not Eligible for Intensive Chemotherapy

2019-06-01 09:31:01 | Agios Pharmaceuticals AGIO Down 8% Since Last Earnings Report: Can It Rebound?

2019-06-01 08:02:30 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-05-16 10:49:02 | Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study

2019-05-16 07:40:02 | The Daily Biotech Pulse: FDA Nod For Roche, Trial Results For Agios, Iovance And MacroGenics

2019-05-15 23:39:03 | Alibaba, Cisco, Agios Pharmaceuticals and More: Why These Stocks Are in the Spotlight

2019-05-15 17:41:30 | Stocks making the biggest moves after hours: Agios, Farfetch, Cisco and more

2019-05-15 16:05:00 | Agios to Present Clinical Data from its IDH Program at ASCO

2019-05-15 16:01:00 | Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® ivosidenib Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

2019-05-14 11:22:45 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-05-07 08:04:53 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-05-04 01:17:15 | Edited Transcript of AGIO earnings conference call or presentation 2-May-19 12:00pm GMT

2019-05-03 10:19:02 | Agios AGIO Earnings and Revenues Surpass Estimates in Q1

2019-05-02 14:59:12 | Agios Pharmaceuticals Inc AGIO Q1 2019 Earnings Call Transcript

2019-05-02 13:18:47 | Agios Announces FDA Approval of Supplemental New Drug Application sNDA for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia AML Not Eligible for Intensive Chemotherapy

2019-05-02 10:15:02 | Agios Pharmaceuticals AGIO Reports Q1 Loss, Tops Revenue Estimates

2019-05-02 09:03:21 | Agios Pharmaceuticals: 1Q Earnings Snapshot

2019-05-02 07:00:00 | Agios Reports Business Highlights and First Quarter 2019 Financial Results

2019-05-02 06:00:00 | Agios Pharmaceuticals, Inc. to Host Earnings Call

2019-04-27 09:21:01 | Did Hedge Funds Drop The Ball On Agios Pharmaceuticals Inc AGIO?

2019-04-26 10:30:02 | Earnings Preview: Agios Pharmaceuticals AGIO Q1 Earnings Expected to Decline

2019-04-25 16:00:00 | Agios to Webcast Conference Call of First Quarter 2019 Financial Results on May 2, 2019

2019-04-11 15:27:54 | What Are Analysts Saying About Agios Pharmaceuticals, Inc.'s NASDAQ:AGIO Earnings Outlook?

2019-04-09 10:47:38 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-04-02 16:00:00 | Agios Announces New Commercial Leadership Structure

2019-04-02 10:09:02 | AVEO Reports Positive Results on Leukemia Drug, Shares Up

2019-03-27 10:48:02 | Agios AGIO Surges More Than 40% Year to Date: Here's Why

2019-03-27 10:45:02 | Agios Gains Breakthrough Therapy Status for Tibsovo Combo

2019-03-26 16:00:00 | Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® ivosidenib in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia AML with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy

2019-03-26 08:57:08 | See what the IHS Markit Score report has to say about Agios Pharmaceuticals Inc.

2019-03-16 09:30:01 | Why Is Agios Pharmaceuticals AGIO Up 13.2% Since Last Earnings Report?

2019-03-06 14:01:46 | All You Need To Know About Agios Pharmaceuticals, Inc.’s NASDAQ:AGIO Financial Health

2019-03-04 07:00:00 | Agios to Present at the Cowen 39th Annual Health Care Conference on Monday, March 11, 2019

2019-02-25 07:00:00 | Agios Reports Updated Data from Phase 1 Study of Ivosidenib in Combination with Azacitidine Demonstrating Deep and Durable Responses in Newly Diagnosed IDH1 Mutant Acute Myeloid Leukemia AML Patients

2019-02-22 07:25:00 | Analysis: Positioning to Benefit within Quest Diagnostics, Autodesk, Agios Pharmaceuticals, AMN Healthcare Services, Vistra Energy, and Helen of Troy — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-21 09:34:02 | Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer

2019-02-21 07:00:00 | Agios to Present at the Leerink Global Healthcare Conference on Thursday, February 28, 2019

2019-02-20 15:43:40 | Edited Transcript of AGIO earnings conference call or presentation 14-Feb-19 1:00pm GMT

2019-02-20 07:00:00 | Agios Announces FDA Acceptance of Supplemental New Drug Application for TIBSOVO® ivosidenib for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy

2019-02-15 14:25:07 | Agios AGIO Q4 Earnings Beat, Tibsovo Sales Push Up Stock